Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 64

Sort by

Sort Order Select

Journal Articles

Treatment with sirolimus for refractory/relapsed primary or secondary warm autoimmune hemolytic anemia/evans syndrome: A single centre prospective study

Qi Wang, Miao Chen, Junling Zhuang, Chen Yang, ziwei liu, Bing Han

Blood (2025) 146 (Supplement 1): 4666.

https://doi.org/10.1182/blood-2025-4666

Published: 2025

Journal Articles

Selinexor in combination with azacitidine or Ruxolitinib for Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes: A Multi-Center Prospective Exploratory Study

Xijuan Lin, Ziwei Liu, Chen Yang, Junling Zhuang, Na Wei, Tingting Cui, Wenqi Zheng, Fang Ye, Xiaoqing Ding, Miao Chen, Bing Han

Blood (2025) 146 (Supplement 1): 5624.

https://doi.org/10.1182/blood-2025-5624

Published: 2025

Journal Articles

Real-world outcomes with eliglustat for gaucher disease type 1 in China: A multicenter retrospective study

Yongxin Zhou, Zijian Hao, Zhuang Qilin, Miao Chen, Junling Zhuang, Bing Han

Blood (2025) 146 (Supplement 1): 7980.

https://doi.org/10.1182/blood-2025-7980

Published: 2025

Journal Articles

Efficacy and safety of bruton tyrosine kinase (BTK) inhibitor zanubrutinib in relapsed/refractory warm autoimmune hemolytic anemia (wAIHA) after multiple lines of therapy: A prospective phase 2 single-arm study

Miao Chen, Ziwei Liu, Chen Yang, Junling Zhuang, Bing HAN

Blood (2025) 146 (Supplement 1): 1104.

https://doi.org/10.1182/blood-2025-1104

Published: 2025

Journal Articles

Efficacy and safety of romiplostim N01 for refractory aplastic anemia: A retrospective single‑center study

Zhuang Qilin, Ziwei Liu, Chen Yang, Miao Chen, Junling Zhuang, Bing Han

Blood (2025) 146 (Supplement 1): 1416.

https://doi.org/10.1182/blood-2025-1416

Published: 2025

Journal Articles

Beyond the unknown: Leveraging machine learning to predict adverse outcomes in pregnant women with aplastic anemia from a representative nationwide cohort

Blood (2025) 146 (Supplement 1): 1413.

https://doi.org/10.1182/blood-2025-1413

Published: 2025

Journal Articles

KP104, a bifunctional C5 mAb–Factor h fusion protein, demonstrates sustained long-term efficacy and safety in complement inhibitor–naïve PNH patients: 2-year results from A phase 2 study with 8-week post-treatment safety follow-up.

Li Zhang, Chen Yang, Changhe Yue, Jay Ma, Chaomei He, Ping Tsui, Helen Fu, Angela Yan, Wenru Song, Fengkui Zhang, Bing Han

Blood (2025) 146 (Supplement 1): 1118.

https://doi.org/10.1182/blood-2025-1118

Published: 2025

Journal Articles

Pregnancy outcomes after crovalimab exposure: Analysis of animal model and clinical trial data suggest no adverse effects in paroxysmal nocturnal hemoglobinuria

Erfan Nur, Zenghua Lin, Martin Bopst, Sai Li, Sasha Sreckovic, Bing HAN

Blood (2025) 146 (Supplement 1): 3203.

https://doi.org/10.1182/blood-2025-3203

Published: 2025

Journal Articles

Correlation between efficacy, clonal dynamics evolution, and development of bone marrow failure in PNH/AA syndrome treated with complement inhibitors: A single-center cohort study

Chen Yang, Bing Han

Blood (2025) 146 (Supplement 1): 4987.

https://doi.org/10.1182/blood-2025-4987

Published: 2025

Journal Articles

Serum ferritin changes in iptacopan-treated patients with paroxysmal nocturnal hemoglobinuria

Antonio Risitano, Carlos de Castro, Camilla Frieri, Bing Han, Richard Kelly, Austin Kulasekararaj, Jaroslaw Maciejewski, Vinod Pullarkat, Alexander Röth, Phillip Scheinberg, Flore Sicre-de-Fontbrune, Yasutaka Ueda, Tim Costigan, Marion Dahlke, Philippe Ferber, Tomasz Lawniczek, Stefanie Senger, Regis Peffault De Latour

Blood (2025) 146 (Supplement 1): 4974.

https://doi.org/10.1182/blood-2025-4974

Published: 2025

Journal Articles

VSA012, a CFB-targeted siRNA, demonstrates a favorable safety profile and sustained efficacy in PNH patients: Interim Analysis from a Phase Ib Study

Neng Nie, Chen Yang, Jun Shi, WANG Shunqing, Ruiqing Zhou, Hongyan Tong, Hong Chang, Dong You, Jin Chen, Jing Hao, Bing Han

Blood (2025) 146 (Supplement 1): 381.

https://doi.org/10.1182/blood-2025-381

Published: 2025

Journal Articles

The 2-year efficacy and safety of iptacopan monotherapy in patients with paroxysmal nocturnal hemoglobinuria with a history of aplastic anemia on concomitant immunosuppressive therapy who entered the roll-over extension program

Regis Peffault De Latour, Carlos de Castro, Anna Gaya, Morag Griffin, Bing Han, Austin Kulasekararaj, Jaroslaw Maciejewski, Bhumika Patel, Alexander Röth, Phillip Scheinberg, Hubert Schrezenmeier, Yasutaka Ueda, Tim Costigan, Marion Dahlke, Philippe Ferber, Rajeshri Karki, Luca Monaco, Silvia Sanz, Antonio Risitano

Blood (2025) 146 (Supplement 1): 4978.

https://doi.org/10.1182/blood-2025-4978

Published: 2025

Journal Articles

Long-term efficacy and safety of rilzabrutinib, an oral bruton tyrosine kinase (BTK) inhibitor in patients with warm autoimmune hemolytic anemia (wAIHA) in the LUMINA Phase 2b part B study: A 74-week follow-up

Bruno Fattizzo, Henrik Frederiksen, Alessandro Lucchesi, Bing Han, Catherine Broome, Nicola Cooper, Joan Cid, Frederick Chen, Amitabha Mazumder, Míriam Vara Pampliega, Deepthi Jayawardene, Heidi Krenz, Jing Zhao, Ahmed Daak, David Kuter

Blood (2025) 146 (Supplement 1): 4655.

https://doi.org/10.1182/blood-2025-4655

Published: 2025

Journal Articles

Rbm38 Deficiency Impairs Erythroid Heme Biosynthesis and Induces Porphyria via Reduced Ferrochelatase Expression

Blood blood.2025028783.

https://doi.org/10.1182/blood.2025028783

Published: 2025

Includes: Supplemental data

Journal Articles

Effective Treatment of Refractory Aplastic Anemia with Romiplostim after Failure of Multiple Thrombopoietin Receptor Agonists: A Single-Center Retrospective Study

Xijuan Lin, Chen Yang, Ziwei Liu, Junling Zhuang, Miao Chen, Bing Han

Blood (2024) 144 (Supplement 1): 4077.

https://doi.org/10.1182/blood-2024-200421

Published: 2024

Journal Articles

Hetrombopag Added to Immunosuppressive Therapy in First-Line Treatment of Severe Aplastic Anemia: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial

Blood (2024) 144 (Supplement 1): 304.

https://doi.org/10.1182/blood-2024-206377

Published: 2024

Journal Articles

Oral Iptacopan Monotherapy Leads to Long-Term Improvements in Patient (Pt)-Reported Health-Related Quality of Life (HRQoL) and Investigator-Assessed Signs and Symptoms of Paroxysmal Nocturnal Hemoglobinuria (PNH): 48-Week (Wk) Results from the Phase III APPLY-PNH and APPOINT-PNH Trials

Antonio M Risitano, Bing Han, Austin G. Kulasekararaj, Yasutaka Ueda, Phillip Scheinberg, Carlos de Castro, Jaroslaw Maciejewski, Josefin Snellman, Olivier Somenzi, Randall Winnette, Samopriyo Maitra, Shujie Li, Marion Dahlke, Regis Peffault De Latour

Blood (2024) 144 (Supplement 1): 4079.

https://doi.org/10.1182/blood-2024-203532

Published: 2024

Journal Articles

KP104, a Bifunctional C5 Mab-Factor H Fusion Protein, Demonstrates Sustained Long-Term Efficacy and Safety in Complement Inhibitor-Naïve PNH Patients: Updated Results from a Phase 2 Study at 36/38 Weeks of Obd Treatment

Fengkui Zhang, Li Zhang, Chen Yang, Changhe Yue, Jay Ma, Chaomei He, Ping Tsui, Qing Yu Christina Weng, Helen Fu, Hui Yan, Wenru Song, Bing Han

Blood (2024) 144 (Supplement 1): 2699.

https://doi.org/10.1182/blood-2024-210086

Published: 2024

Journal Articles

Adding Eltrombopag to Intensive Immunosuppressive Therapy Helps Adult Patients Catch up Pediatric Patients in Severe Aplastic Anemia

Bixi Yang, Leyu Wang, Lingling Fu, Runhui Wu, Jie Ma, Miao Chen, Bing Han

Blood (2024) 144 (Supplement 1): 5247.

https://doi.org/10.1182/blood-2024-193483

Published: 2024

Journal Articles

Long-Term Real-World Follow-up Study of Luspatercept for Lower-Risk Myelodysplastic Neoplasms

Zhuxin Zhang, Leyu Wang, Ziwei Liu, Chen Yang, Miao Chen, Bing Han, Junling Zhuang

Blood (2024) 144 (Supplement 1): 6730.

https://doi.org/10.1182/blood-2024-199403

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Treatment with sirolimus for refractory/relapsed primary or secondary warm autoimmune hemolytic anemia/evans syndrome: A single centre prospective study

Selinexor in combination with azacitidine or Ruxolitinib for Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes: A Multi-Center Prospective Exploratory Study

Real-world outcomes with eliglustat for gaucher disease type 1 in China: A multicenter retrospective study

Efficacy and safety of bruton tyrosine kinase (BTK) inhibitor zanubrutinib in relapsed/refractory warm autoimmune hemolytic anemia (wAIHA) after multiple lines of therapy: A prospective phase 2 single-arm study

Efficacy and safety of romiplostim N01 for refractory aplastic anemia: A retrospective single‑center study

Beyond the unknown: Leveraging machine learning to predict adverse outcomes in pregnant women with aplastic anemia from a representative nationwide cohort

KP104, a bifunctional C5 mAb–Factor h fusion protein, demonstrates sustained long-term efficacy and safety in complement inhibitor–naïve PNH patients: 2-year results from A phase 2 study with 8-week post-treatment safety follow-up.

Pregnancy outcomes after crovalimab exposure: Analysis of animal model and clinical trial data suggest no adverse effects in paroxysmal nocturnal hemoglobinuria

Correlation between efficacy, clonal dynamics evolution, and development of bone marrow failure in PNH/AA syndrome treated with complement inhibitors: A single-center cohort study

Serum ferritin changes in iptacopan-treated patients with paroxysmal nocturnal hemoglobinuria

VSA012, a CFB-targeted siRNA, demonstrates a favorable safety profile and sustained efficacy in PNH patients: Interim Analysis from a Phase Ib Study

The 2-year efficacy and safety of iptacopan monotherapy in patients with paroxysmal nocturnal hemoglobinuria with a history of aplastic anemia on concomitant immunosuppressive therapy who entered the roll-over extension program

Long-term efficacy and safety of rilzabrutinib, an oral bruton tyrosine kinase (BTK) inhibitor in patients with warm autoimmune hemolytic anemia (wAIHA) in the LUMINA Phase 2b part B study: A 74-week follow-up

Rbm38 Deficiency Impairs Erythroid Heme Biosynthesis and Induces Porphyria via Reduced Ferrochelatase Expression

Effective Treatment of Refractory Aplastic Anemia with Romiplostim after Failure of Multiple Thrombopoietin Receptor Agonists: A Single-Center Retrospective Study

Hetrombopag Added to Immunosuppressive Therapy in First-Line Treatment of Severe Aplastic Anemia: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial

Oral Iptacopan Monotherapy Leads to Long-Term Improvements in Patient (Pt)-Reported Health-Related Quality of Life (HRQoL) and Investigator-Assessed Signs and Symptoms of Paroxysmal Nocturnal Hemoglobinuria (PNH): 48-Week (Wk) Results from the Phase III APPLY-PNH and APPOINT-PNH Trials

KP104, a Bifunctional C5 Mab-Factor H Fusion Protein, Demonstrates Sustained Long-Term Efficacy and Safety in Complement Inhibitor-Naïve PNH Patients: Updated Results from a Phase 2 Study at 36/38 Weeks of Obd Treatment

Adding Eltrombopag to Intensive Immunosuppressive Therapy Helps Adult Patients Catch up Pediatric Patients in Severe Aplastic Anemia

Long-Term Real-World Follow-up Study of Luspatercept for Lower-Risk Myelodysplastic Neoplasms

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only